We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.04 | 0.16% | 25.68 | 25.83 | 25.585 | 25.67 | 38,018,692 | 00:59:54 |
From May 2019 to May 2024
By Chelsey Dulaney
Pfizer Inc. said Friday that two late-stage studies for its Trumenba meningitis B vaccine met their primary endpoint goals, showing "robust immune responses" against some strains of meningococcal disease.
One study included 3,600 healthy individuals ages 10 through 18, while the other included 3,300 individuals aged 18 through 25.
Kathrin Jansen, senior vice president of vaccine research and development for Pfizer, said the data supports vaccination of adolescents and young adults to prevent meningococcal disease.
Trumenba was granted accelerated approval by the U.S. Food and Drug Administration in October 2014 for 10-25-year-olds.
Pfizer has been focusing on building its meningitis vaccine program lately.
In June, Pfizer agreed to buy two meningitis vaccines from GlaxoSmithKline PLC for about $130 million. The acquisition followed Pfizer's purchase last year of Baxter International Inc.'s meningococcal disease vaccine NeisVac-C.
Write to Chelsey Dulaney at Chelsey.Dulaney@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
August 21, 2015 09:01 ET (13:01 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
